ClinicalTrials.gg
RecruitingNCT07749651Updated Aug 31, 2026

A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults

A Phase 1 interventional study of SHR-7012 injection ; placebo and SHR-7012 injection ; placebo in Cutaneous Lupus Erythematosus(CLE), sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Lupus Erythematosus, Cutaneous with a site in China — 7 open to participants now, 10 under way, 5 of them phase 3. Lupus Erythematosus, Cutaneous · China.

Planned enrollment
10th of 12
50 · median 202
Started
2026
with 4 others
Phase 1
2 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Guangdong Hengrui Pharmaceutical Co., Ltd

Among the 12 studies in Lupus Erythematosus, Cutaneous with a site in China, this one is the 10th largest by planned enrollment, is one of 5 that started in 2026, is one of 2 in phase 1, and was the 11th registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

7 of the 12 studies in Lupus Erythematosus, Cutaneous with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Lupus Erythematosus, Cutaneous with a site in China, or all of them as a file.
02

Study summary

A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults

03

Conditions studied

  • Cutaneous Lupus Erythematosus(CLE)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of signing the form was between 18 and 55 years old (inclusive), both male and female.
  2. Body weight ≥50 kg for men and ≥45 kg for women during the screening period, (BMI = weight (kg)/ height 2(m2)) between 19.0 and 26.0 kg/m2 (including boundary value)
  3. Female participants of and male participants whose partners were fertile women had no plans to give birth, sperm or egg donation within 6 months after signing the informed consent, and voluntarily took highly effective methods. Female participants of childbearing potential had to have a serum pregnancy test with a negative result during the screening and baseline periods
  4. Female participants: not pregnant or lactatin
  5. Before the trial, the participants had understood the nature, significance, possible benefits, possible inconvenience, potential risks and discomfort of the trial in detail, were able to understand the procedures and methods of the study, were willing to strictly abide by the requirements of the entire clinical study, and voluntarily signed informed consent

Exclusion criteria

Exclusion Criteria:

  1. Patients with previous or current clinical acute or chronic diseases of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry, or metabolic disorders, who were judged by the investigator to be unsuitable for enrollment
  2. Patients had a history of severe herpesvirus infection, a history of , or current active infection
  3. Patients with chronic or recurrent infection requiring treatment within 12 months before screening
  4. A screening test for tuberculosis infection (interferon-γ release assay, IGRA) was positive
  5. There was a previous history of risk factors for torsades de pointes
  6. Patients who had undergone major surgery within 6 months before screening
  7. Persons who had been vaccinated within 1 month before screening or planned to be vaccinated during the trial
  8. Anyone who had taken any medication or health product (including Chinese herbal medicine) within 7 half-lives or 14 days before dose, whichever was longer, or who had known during the screening period that they might need to receive additional medication during the trial
  9. Participants who had participated in a clinical trial and received a trial drug within 3 months before screening or who planned to participate in another clinical trial during the trial
  10. Patients were screened if they had donated or lost at least 400 mL of blood (except physiological blood loss in women) within 3 months before the trial, received a transfusion or used blood products, or were planning to donate blood during or within 1 month after the trial
  11. People who have special dietary requirements and cannot follow a uniform diet
  12. Those with a history of drug abuse, drug use, or a positive screening test for drug abuse
  13. Those who have difficulty in venous blood collection/cannot tolerate venipuncture, or have a history of fainting or fainting
  14. If the site of administration was abnormal, the investigator judged that subcutaneous administration was not suitable
  15. Participants may have been unable to complete the study for other reasons or may have been deemed by the investigator to be unsuitable for enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment group 1: Dose1 Injection of SHR-7012 or placebo

    Drug: SHR-7012 injection ; placebo

  • Experimental
    Treatment group 2: Dose2 Injection of SHR-7012 or placebo

    Drug: SHR-7012 injection ; placebo

  • Experimental
    Treatment group 3: Dose3 Injection of SHR-7012 or placebo

    Drug: SHR-7012 injection ; placebo

  • Experimental
    Treatment group 4: Dose4 Injection of SHR-7012 or placebo

    Drug: SHR-7012 injection ; placebo

  • Experimental
    Treatment group 5: Dose5 Injection of SHR-7012 or placebo

    Drug: SHR-7012 injection ; placebo ;

Interventions

  • DrugSHR-7012 injection ; placebo

    A single subcutaneous injection of Dose1 SHR-7012 injection or placebo was administered

  • DrugSHR-7012 injection ; placebo

    A single subcutaneous injection of Dose2 SHR-7012 injection or placebo was administered

  • DrugSHR-7012 injection ; placebo

    A single subcutaneous injection of Dose3 SHR-7012 injection or placebo was administered

  • DrugSHR-7012 injection ; placebo

    A single subcutaneous injection of Dose4 SHR-7012 injection or placebo was administered

  • DrugSHR-7012 injection ; placebo ;

    A single subcutaneous injection of Dose5 SHR-7012 injection or placebo was administered

06

What researchers measure

Primary outcomes

  1. Safety and tolerability : Incidence and severity of any adverse events

    Time frame: Evaluation was performed up to Day141

Secondary outcomes

  1. AUC0-t

    Time frame: Evaluation was performed up to Day113 or Day141

  2. AUC0 ∞

    Time frame: Evaluation was performed up to Day113 or Day141

  3. Tmax

    Time frame: Evaluation was performed up to Day113 or Day141

  4. Cmax

    Time frame: Evaluation was performed up to Day113 or Day141

  5. t1/2

    Time frame: Evaluation was performed up to Day113 or Day141

  6. λz

    Time frame: Evaluation was performed up to Day113 or Day141

  7. CL/F

    Time frame: Evaluation was performed up to Day113 or Day141.

  8. Vz/F

    Time frame: Evaluation was performed up to Day113 or Day141.

  9. MRT0-t

    Time frame: Evaluation was performed up to Day113 or Day141.

  10. MRT0-∞

    Time frame: Evaluation was performed up to Day113 or Day141.

  11. AUC%Extrap

    Time frame: Evaluation was performed up to Day113 or Day141.

  12. Antidrug antibody (ADA)

    Time frame: Evaluation was performed up to Day113 or Day141.

  13. Neutralizing antibody (NAb)

    Time frame: Evaluation was performed up to Day113 or Day141.

07

Study locations

1 of 1 sites recruiting
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 314408, China
    Recruiting
    • Yiwen Zhang · Principal investigator
    • Ping Huang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Apr 2027, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartActual
Aug 19, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Aug 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07749651
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Aug 19, 2026
Primary completion
Apr 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Yuqing Huang
Contact
yuqing.huang@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion